"To join Boehringer Ingelheim was the best ever decision"
Pharmacologist Michael Mark worked for us for 34 years. He played a key role in the research and development of several medications. Watch our video and discover our job opportunities.
Search
Iclepertin: GlyT1 inhibitor
Iclepertin: GlyT1 inhibitor
CT-155: Prescription digital therapeutic
CT-155: Prescription digital therapeutic
Joint venture to fight Antimicrobial Resistance
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
Partnership canine oncology
The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
Making a difference with data science
Our Head of Central Data Science, Brigitte Fuhr joined the team to make a difference to patients’ lives.
EMPRISE-Study
EMPRISE-Study
FDA approves Jardiance treatment chronic kidney disease
U.S. FDA approves Jardiance® for treatment of adults with chronic kidney disease
cat feline diabetes medication treatment eu approval
Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats
LastMile – improving through digital
LastMile initiative is an integrated, solutions-driven program seeking to make animal medical resources available in hard-to-reach areas in Africa.
COVID-19 Material donations in Germany
Partnership for new liver disease treatments with Ribo
Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases
Over 100 billion birds vaccinated with VAXXITEK
Boehringer Ingelheim celebrates that over 100 billion birds have been vaccinated with VAXXITEK® HVT + IBD in October 2018.
Waste
Resource conservation at Boehringer Ingelheim is managed as part of an ongoing process of prevention and reduction of material usage and waste.
empulse-trial-benefit-acute-heart-failure
Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
preserved-heart-failure-treatment-approval-europe
preserved-heart-failure-treatment-approval-europe
emperor-preserved-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Preserved Phase III trial in adults with heart failure with preserved ejection fraction
New indications NexGard, NexGard SPECTRA and Broadline
New therapeutic indications for NexGard®, NexGard SPECTRA® and Broadline® approved by EMA
New cancer therapeutics collaboration with 3T Bio
Boehringer Ingelheim and 3T Biosciences collaborate to discover and develop next-generation cancer therapies to address high unmet patient needs
Celebrating 20 years of Metacam for cattle
Celebrating 20 years of Metacam (Meloxicam) for cattle
Purevax range now available in 0.5 ml presentation
Boehringer Ingelheim announces reduced volume 0.5 ml Purevax vaccines for cats, more convenient vaccination experience combined with same efficacy
New African Swine Fever Manual published
Boehringer Ingelheim joined forces with the leading veterinarians to fight African swine fever. The new African Swine Fever Knowledge Handbook published.
Launch of BVDzero scholarship for veterinary students
Launch of BVDzero scholarship for veterinary students globally
Advancing health equity for rural doctors in Mexico
Our virtual sales team helps doctors stay informed through digital education about the latest treatments, regardless of their location
Boehringer expands cancer research at Vienna site
Boehringer Ingelheim expands cancer research at its Vienna site